Despite the proven favourable risk–benefit ratio, thrombolytic therapy for acute stroke is perceived to carry a grave risk. A simple risk-rating system, the SEDAN score, allows clinicians to quantify elevated risk. Whether effective thrombolytic therapy should be withheld from any particular patient requires further study, including randomized trials of patients with elevated risk scores.
